The Indian Health Regulator Drug Controller General of India (DCGI) has asked Natco Pharma to stop marketing the breast cancer drug 'Albupax'. The company said it was stopping production of the drug after research indicated that it may cause liver damage.
As per DCGI office, we have stopped marketing the product in the interim," Natco Pharma said.
"Natco maintains its product passes all quality parameters. The test methods used to test a nano technology product are complex."
Natco initially introduced the drug in India last October and had tied up with Dr Reddy's Laboratories for a US launch.
The company also indicated that the revenues generated by the drug were insignificant and that its removal from the market would not affect its bottom line.